Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRingash, Jolie*
dc.contributor.authorAu, Heather-Jane*
dc.contributor.authorSiu, Lillian L.*
dc.contributor.authorShapiro, Jeremy D.*
dc.contributor.authorJonker, Derek J.*
dc.contributor.authorZalcberg, John R.*
dc.contributor.authorMoore, Malcolm J.*
dc.contributor.authorStrickland, Andrew*
dc.contributor.authorKotb, Rami*
dc.contributor.authorJeffrey, Mark*
dc.contributor.authorAlcindor, Thierry*
dc.contributor.authorNg, Siobhan*
dc.contributor.authorSalim, Muhammad*
dc.contributor.authorSabesan, Sabe*
dc.contributor.authorEasaw, Jay C.*
dc.contributor.authorShannon, Jenny*
dc.contributor.authorEl-Tahche, Fabyolla*
dc.contributor.authorWalters, Ian*
dc.contributor.authorDongsheng, Tu*
dc.contributor.authorO'Callaghan, Christopher J.*
dc.description.abstractBACKGROUND: The CO.20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET=placebo). METHODS: Quality of life (QoL) was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 at baseline and at 2, 4, 6, 8, 12, 16, and 24 weeks until disease progression. Predefined coprimary QoL endpoints were time to deterioration (first worsening from baseline of 10 points) on the Physical Function (PF) and Global (GHS) scales. RESULTS: Of 750 randomized patients, 721 (358 of whom received CET=BRIV) were assessable for QoL. QoL compliance and baseline PF and GHS scores did not differ by treatment arm. The median time to deterioration was 1.6 months versus 1.1 months for GHS (P5.02) and 5.6 months versus 1.7 months for PF (P<.0001) favoring CET=placebo. Secondary analysis favored CET=placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales. A greater percentage of patients on the CET=BRIV arm had PF worsening at 6 weeks (31% vs 17%). Clinical adverse events of grade 3 were more common with CET=BRIV than with CET=placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia. CONCLUSIONS: Compared with CET=placebo, the combination of CET=BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30. This result may be due to higher rates of fatigue and gastrointestinal adverse events. Cancer 2014;120:181–9. VC 2013 American Cancer Society. KEYWORDS: colorectal cancer, K-RAS, palliative chemotherapy, quality of life, questionnaires, patient-reported outcomes.en
dc.description.provenanceSubmitted by Gemma Siemensma ( on 2014-06-19T05:00:21ZNo. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma ( on 2014-09-01T06:05:13Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2014-09-01T06:05:13Z (GMT). No. of bitstreams: 0 Previous issue date: 2014en
dc.publisherWiley Online Libraryen
dc.titleQuality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.en
dc.typeJournal Articleen
dc.contributor.corpauthorAmerican Cancer Societyen
dc.contributor.corpauthorAustralasian Gastrointestinal Trials Groupen
dc.contributor.corpauthorNCIC Clinical Trials Groupen
dc.publisher.placeHoboken, N.J.en
dc.subject.healththesaurusCOLORECTAL CANCERen
dc.subject.healththesaurusPALLIATIVE CHEMOTHERAPYen
dc.subject.healththesaurusQUALITY OF LIFEen
dc.subject.healththesaurusPATIENT-REPORTED OUTCOMESen
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.